Back to search

Aristotle University Of Thessaloniki (AUTH)

Συσχέτιση πολυμορφισμών γονιδίων που εμπλέκονται στη δράση ινκρετινο-μιμητικών φαρμάκων, με την αποτελεσματικότητά τους σε ασθενείς με σακχαρώδη διαβήτη τύπου 2

Abstract

dc:description

Type 2 diabetes mellitus (T2DM) is a chronic, multifactorial disease with a strong genetic background. Environmental factors play a decisive role in its manifestation, with obesity being the most common cause of the disease. A basic complication of diabetes is vasculopathy, which, in combination with obesity, increases the cardiovascular risk which is the main cause of death in patients with T2DM. The regulation of glucose levels (fasting and postprandial) leads to better glycemic control and reduces the risk of complications in patients with T2DM and is the goal of classical pharmaceutical treatments.At the same time, however, classic antidiabetic tablets (sulfonylureas) lead to the appearance of hypoglycemic episodes and an increase in body weight in patients, while their effect on cardiovascular risk has not been clarified. In the last 20 years, new pharmaceutical agents have been used in the treatment of T2DM. These agents are called incretin analogues (mainly GLP-1 and recently GIP) and constitute substances that imitate peptides that are secreted by the intestinal mucosa and induce insulin secretion after eating, regulating postprandial glucose levels and control of lipid metabolism. The administration of analogues to GLP-1 has been shown to stimulate insulin secretion in a glucose-dependent manner, improving the glycemic profile of patients, while at the same time suppressing glucagon secretion, reducing gastric emptying and increasing the feeling of satiety, contributing to the regulation of the body weight of the patients. It has been observed, however, that the response of patients to treatment with GLP-1 analogues shows significant heterogeneity even between individuals with similar glycemic control or similar antidiabetic treatment requirements.The heterogeneity observed both in terms of response and/or resistance to treatment, and in side effects observed from patient to patient, is most likely related to the different genetic background of the patients regarding to genes involved in incretin pathway. Recent in vitro studies have shown that single nucleotide polymorphisms (SNPs) in the GLP-1 receptor genes either alter the chemical affinity of the receptor for the GLP-1 peptide affecting its ability to bind to the receptor, or affect the activity of the natural ligand.Additionally, studies on the TCF7L2 gene have shown that patients with type 2 diabetes who carry the TCF7L2rs7903146 allele show significantly reduced GLP-1-induced insulin secretion. Also, polymorphisms in the CTBR1/2 genes have been found to influence the susceptibility of patients to this disease. In the present PhD thesis, the main research question was the role of single nucleotide polymorphisms (SNPs) rs7903146 in the gene of transcription factor TCF7L2, rs367543060 in the GLP-1R receptor gene, and rs7202877 in the CTRB1/2 gene, on the hypoglycemic effect of GLP-1 analogs and/or their effect on weight reduction in T2DM patients. In order to investigate this question, the relationship between the above genetic polymorphisms and the heterogeneous therapeutic response in glycemia and body weight was examined in 191 Caucasian patients to whose treatment a GLP-1 analog was added, without performing any therapeutic or other intervention on the already existing treatment regimen. In addition, a number of clinical parameters were examined in order to identify potential predictors of response to treatment with GLP-1 analogues. Participants were initially categorized into responders and non-responders to GLP-1 analogue therapy with regard to glycemic control (Group A1 and A2, respectively). Patients were then further divided into two groups according to their response to GLP-1 analogue therapy in terms of weight loss, regardless of their response to glycemic control (Group B1 and B2, respectively). The genotyping of the rs7202877, rs7903146 and rs367543060 polymorphisms was performed at the General Biology Laboratory of the Department of Medicine, University of Patras. Genomic DNA was obtained from a venous blood sample of each patient, extracted and quantified, and DNA genotyping was then performed using the Real-Time PCR (Real-Time PCR) technique. The results of our study showed that: a) the polymorphisms in the genes examined do not seem to be related to the response of patients to treatment with GLP-1 analogues, b) a greater percentage of women are likely to respond to the treatment in terms of regarding glycemia compared to men, c) patients with a lower body weight at the beginning of treatment were more likely to respond to GLP-1 treatment proportionally in terms of weight regulation;d) a lower value of FPG at the start of treatment increases the chances of response to treatment in terms of weight regulation, e) a lower value of glycated hemoglobin at the start of treatment with GLP-1 analogues, increases the chances that patients will respond to weight management treatment, f) patients who had received fewer medical agents before starting their treatment with GLP-1 analogues (early inclusion of a GLP-1 analogue in the treatment), appear to be more likely to respond to this treatment, in terms of weight regulation.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kyriazou, Angeliki
  • Κυριάζου, Αγγελική

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/54173

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kyriazou, Angeliki; Κυριάζου, Αγγελική. Συσχέτιση πολυμορφισμών γονιδίων που εμπλέκονται στη δράση ινκρετινο-μιμητικών φαρμάκων, με την αποτελεσματικότητά τους σε ασθενείς με σακχαρώδη διαβήτη τύπου 2. Aristotle University Of Thessaloniki (AUTH), 2023. http://hdl.handle.net/10442/hedi/54173